[en] CONTEXT: An association between germline aryl hydrocarbon receptor-interacting protein (AIP) gene mutations and pituitary adenomas was recently shown. OBJECTIVE: The objective of the study was to assess the frequency of AIP gene mutations in a large cohort of patients with familial isolated pituitary adenoma (FIPA). DESIGN: This was a multicenter, international, collaborative study. SETTING: The study was conducted in 34 university endocrinology and genetics departments in nine countries. PATIENTS: Affected members from each FIPA family were studied. Relatives of patients with AIP mutations underwent AIP sequence analysis. MAIN OUTCOME MEASURES: Presence/absence and description of AIP gene mutations were the main outcome measures. INTERVENTION: There was no intervention. RESULTS: Seventy-three FIPA families were identified, with 156 patients with pituitary adenomas; the FIPA cohort was evenly divided between families with homogeneous and heterogeneous tumor expression. Eleven FIPA families had 10 germline AIP mutations. Nine mutations, R16H, G47_R54del, Q142X, E174frameshift, Q217X, Q239X, K241E, R271W, and Q285frameshift, have not been described previously. Tumors were significantly larger (P = 0.0005) and diagnosed at a younger age (P = 0.0006) in AIP mutation-positive vs. mutation-negative subjects. Somatotropinomas predominated among FIPA families with AIP mutations, but mixed GH/prolactin-secreting tumors, prolactinomas, and nonsecreting adenomas were also noted. Approximately 85% of the FIPA cohort and 50% of those with familial somatotropinomas were negative for AIP mutations. CONCLUSIONS: AIP mutations, of which nine new mutations have been described here, occur in approximately 15% of FIPA families. Although pituitary tumors occurring in association with AIP mutations are predominantly somatotropinomas, other tumor types are also seen. Further study of the impact of AIP mutations on protein expression and activity is necessary to elucidate their role in pituitary tumorigenesis in FIPA.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
Publication date :
May 2007
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Volume :
92
Issue :
5
Pages :
1891-1896
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Cet article a bénéficié d'un éditorial de : S. Melmed - University of California - Los Angeles. Aryl Hydrocarbon Receptor Interacting Protein and Pituitary Tumorigenesis : Another Interesting Protein Editorial publié dans J. Clin. Endocrinol. Metab., vol 92 ; n°5 2007 : 1617-1619.
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101:613-619
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High prevalence of pituitary adenomas: a cross sectional study in the Province of Liège, Belgium. J Clin Endocrinol Metab 91:4769-4775
Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P 1998 Prognostic and therapeutic consequences of Gs α mutations in somatotroph adenomas. J Clin Endocrinol Metab 83:1604-1610
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L 1989 GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692-696
Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K, Ezzat S 2004 Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904-1911
Pei L, Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11:433-441
Agarwal SK, Lee Burns A, Sukhodolets KE, Kennedy PA, Obungu VH, Hickman AB, Mullendore ME, Whitten I, Skarulis MC, Simonds WF, Mateo C, Crabtree JS, Scacheri PC, Ji Y, Novotny EA, Garrett-Beal L, Ward JM, Libutti SK, Richard Alexander H, Cerrato A, Parisi MJ, Santa Anna-A S, Oliver B, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ 2004 Molecular pathology of the MEN1 gene. Ann NY Acad Sci 1014:189-198
Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A 2002 Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457-465
Stratakis CA, Matyakhina L, Courkoutsakis N, Patronas N, Voutetakis A, Stergiopoulos S, Bossis I, Carney JA 2004 Pathology and molecular genetics of the pituitary gland in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Front Horm Res 32:253-264
Daly AF, Jaffrain-Rea ML, Beckers A 2005 Clinical and genetic features of familial pituitary adenomas. Horm Metab Res 37:347-354
Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA 2000 Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 85:707-714
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228-1230
Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A 2006 Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91:3316-3323
Yu R, Bonert V, Saporta I, Raffel LJ, Melmed S 2006 AIP variants in sporadic pituitary adenomas. J Clin Endocrinol Metab 91:5126-5129
Peltonen L, Palotie A, Lange K 2000 Use of population isolates for mapping complex traits. Nat Rev Genet 1:182-190
Carver LA, LaPres JJ, Jain S, Dunham EE, Bradfield CA 1998 Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem 273:33580-33587
Petrulis JR, Perdew GH 2002 The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact 141:25-40
Bell DR, Poland A 2000 Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90. J Biol Chem 275:36407-36414
Meyer BK, Perdew GH 1999 Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry 38:8907-8917
